Peptides Codex
Home
Research peptide

ARA-290

ARA-290 (cibinetide) is an 11-amino-acid peptide corresponding to the helix-B surface of erythropoietin. It was engineered to engage the tissue-protective innate repair receptor without triggering erythropoiesis, and has been studied in clinical research on neuropathic and inflammatory conditions. It is not authorized by Health Canada for general use.

By The Peptides Codex Editorial TeamReviewed July 10, 2026
Length
11 aa
Class
Research peptide
Function
Innate repair receptor agonist studied in tissue-protection models
Context
Investigational / clinical-stage research compound (not authorized by Health Canada)

EPO-derived peptide designed to keep tissue-protective signaling while avoiding red-blood-cell stimulation.

Also known as: cibinetide · cibinetide (INN)

Part of the Repair & recovery peptides cluster

Overview

ARA-290 (cibinetide) is an 11-amino-acid peptide corresponding to the helix-B surface of erythropoietin. It was engineered to engage the tissue-protective innate repair receptor without triggering erythropoiesis, and has been studied in clinical research on neuropathic and inflammatory conditions. It is not authorized by Health Canada for general use.

Source & context

Biological / chemical source: Synthetic peptide from the helix-B region of erythropoietin

Primary research or clinical context: Investigational / clinical-stage research compound (not authorized by Health Canada)

From erythropoietin to a repair peptide

Researchers isolated the part of the EPO molecule responsible for tissue protection rather than red-cell production and rebuilt it as a short synthetic peptide. ARA-290 selectively activates the innate repair receptor complex implicated in anti-inflammatory and cytoprotective signaling.

Clinical-research status

Under the name cibinetide, ARA-290 has been evaluated in clinical trials for conditions such as sarcoidosis-associated small-fiber neuropathy and holds orphan-drug interest in some jurisdictions. Approval status varies by country; this page is educational and not medical advice.

FAQ about ARA-290

What is ARA-290?+

ARA-290 (cibinetide) is an 11-amino-acid peptide corresponding to the helix-B surface of erythropoietin. It was engineered to engage the tissue-protective innate repair receptor without triggering erythropoiesis, and has been studied in clinical research on neuropathic and inflammatory conditions. It is not authorized by Health Canada for general use.

Is ARA-290 an approved medicine?+

ARA-290 is discussed here as a research / educational topic. Investigational / clinical-stage research compound (not authorized by Health Canada). This is not medical advice.

What is the typical length of ARA-290?+

ARA-290 is commonly described as approximately 11 amino acids (Research peptide).

Related peptides

References & further reading

  1. 1.Wikipedia — Cibinetide
  2. 2.PubChem — compound summary for Cibinetide (CID 91810664)
Disclaimer: Educational content only. Not medical advice. Not instructions for human use. Research peptides and unapproved products may be restricted or illegal to market for human consumption in your jurisdiction. Consult qualified professionals and applicable law.
You might also like: All peptides · Atlas · Research · Tools
Cite this: Peptides Codex — ARA-290 educational profile.
Tip: Use browser print (Ctrl/Cmd + P) for a clean PDF of this page.